Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed

Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01617382

Acronym

HIPEC

Enrollment

125

Registered

2012-06-12

Start date

2012-05-01

Completion date

2028-12-01

Last updated

2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Carcinomatosis, Peritoneal Mesothelioma, Pseudomyxoma Peritonei

Keywords

HIPEC, Hyperthermic (heated) chemotherapy after debulking

Brief summary

The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.

Detailed description

To register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC. In this surgical intervention, the abdominal cavity is macroscopically cleared of tumor, by removing all visible tumor nodules, and is subsequently rinsed with hyperthermic (heated) chemotherapy, aiming to destroy all residual invisible tumor cells that might have stayed behind after the debulking. The eventual aim of this procedure is to improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy

Design outcomes

Primary

Measure	Time frame
To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.	Follow-up over a time period of at least 5 years

Countries

Belgium

Contacts

CONTACTIsabelle B Terrasson

isabelle.terrasson@uzleuven.be+32 16 340837

PRINCIPAL_INVESTIGATORAndré JL D'Hoore, PhD

University Clinics Gasthuisberg Department of Abdominal Surgery

Outcome results